Lv1
66 积分 2023-07-17 加入
P376. Preclinical Pharmacological Characterization of the Selective NR2b Negative Allosteric Modulator BI 1569912 With Potential to Treat MDD
1天前
待确认
Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine–Conjugated RNA Interference Therapeutic
5天前
已完结
Enhanced ERK activity extends ketamine’s antidepressant effects by augmenting synaptic plasticity
5天前
已完结
Target Engagement Measures in Preclinical Drug Discovery: Theory, Methods, and Case Studies
6天前
已完结
Direct crosstalk between GPCRs and ion channels via G proteins
13天前
已完结
The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats
14天前
已完结
The effect of antidepressant treatment on blood BDNF levels in depressed patients: A review and methodological recommendations for assessment of BDNF in blood
15天前
已完结
Design, synthesis, and pharmacological evaluation of novel M4 muscarinic receptor positive allosteric modulators for schizophrenia treatment
22天前
已完结
Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M4 Muscarinic Acetylcholine Receptor
29天前
已完结
Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment
1个月前
已完结
皖公网安备34019202002308
